[en] The biology of peroxisome proliferator activated receptors (PPARs) in physiological and pathophysiological processes has been primarily studied in peripherial organs and tissues. Recently it became clear that PPARs play an important role for the pathogenesis of various disorders of the CNS. The finding that activation of PPARs, and in particular, the PPARgamma isoform, suppresses inflammation in peripherial macrophages and in models of human autoimmune disease, instigated the experimental evaluation of these salutary actions for several CNS disorders that have an inflammatory component. Activation of all PPAR isoforms, but especially of PPARgamma, has been found to be protective in murine in vitro and in vivo models of Multiple Sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in Multiple Sclerosis patients. Likewise, Alzheimer's disease has a prominent inflammatory component that arises in response to neurodegeneration and to extracellular deposition of beta-amyloid peptides. The fact that non steroidal anti-inflammatory drugs (NSAIDs) delay the onset and reduce the risk to develop Alzheimer's disease, while they also bind to and activate PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD may be mediated by PPARgamma. Several lines of evidence from in vitro and in vivo studies have supported this hypothesis, using Alzheimer disease related transgenic cellular and animal models. The ability of PPAR agonists to elicit anti-amyloidogenic, anti-inflammatory and insulin sensitizing effects may account for the observed effects. A number of clinical trials employing PPAR agonists have yielded promising results and further trials are in preparation, which aim to delineate the exact mechanism of interaction. Animal models of other neurodegenerative diseases such as Parkinson's and Amyotrophic lateral sclerosis, both associated with a considerable degree of CNS inflammation, have been studied with a positive outcome. Yet it is not clear whether reduction of inflammation or additional mechanisms account for the observed neuroprotection. Less is known about the physiological role of PPARs for brain development, maintenance and function. Lesions from transgenic mouse models, however, provide evidence that PPARs may play pivotal roles for CNS development and function.
Disciplines :
Neurologie
Auteur, co-auteur :
HENEKA, Michael ; Department of Neurology, Molecular Neurology Unit, Mendelstrasse 7, University of Münster, Albert Schweitzer-Strasse 33, 48149 Münster, Germany. heneka@uni-muenster.de
Landreth, Gary E; Department of Neurosciences, Case Western Reserve University, Cleveland, OH, United States
In: Stewart B.W., and Kleihues P. (Eds). World Cancer Report (2003), IARC Press, Lyon
Akasaki Y., Liu G., Matundan H.H., Ng H., Yuan X., Zeng Z., Black K.L., and Yu J.S. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 281 (2006) 6165
Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383
Allahtavakoli M., Shabanzadeh A.P., Sadr S.S., Parviz M., and Djahanguiri B. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin. Exp. Pharmacol. Physiol. 33 (2006) 1052
Arsenijevic D., de Bilbao F., Plamondon J., Paradis E., Vallet P., Richard D., Langhans W., and Giannakopoulos P. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J. Cereb. Blood Flow Metab. 26 (2006) 433
Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., Laville M., and Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46 (1997) 1319
Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585
Barish G.D. Peroxisome proliferator-activated receptors liver X receptors in atherosclerosis and immunity. J. Nutr. 136 (2006) 690
Barone F.C., and Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 19 (1999) 819
Barone F.C., Hillegass L.M., Tzimas M.N., Schmidt D.B., Foley J.J., White R.F., Price W.J., Feuerstein G.Z., Clark R.K., and Griswold D.E. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol. Chem. Neuropathol. 24 (1995) 13
Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., and Wahli W. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J. Biol. Chem. 274 (1999) 35881
Behin A., Hoang-Xuan K., Carpentier A.F., and Delattre J.-Y. Primary brain tumors in adults. Lancet 361 (2003) 323
Berge K., Tronstad K.J., Flindt E.N., Rasmussen T.H., Madsen L., Kristiansen K., and Berge R.K. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22 (2001) 1747
Bernardo A., and Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006) 93
Bonfigli A., Zarivi O., Colafarina S., Cimini A.M., Ragnelli A.M., Aimola P., Natali P.G., Ceru M.P., Amicarelli F., and Miranda M. Human glioblastoma ADF cells express tyrosinase, l-tyrosine hydroxylase and melanosomes and are sensitive to l-tyrosine and phenylthiourea. J. Cell. Physiol. 207 (2006) 675
Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354
Braissant O., and Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139 (1998) 2748
Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615
Bright J.J., Natarajan C., Muthian G., Barak Y., and Evans R.M. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171 (2003) 5743
Burdge G.C., Rodway H., Kohler J.A., and Lillycrop K.A. Effect of fatty acid supplementation on growth and differentiation of human IMR-32 neuroblastoma cells in vitro. J. Cell. Biochem. 80 (2000) 266
Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908
Cellai I., Benvenuti S., Luciani P., Galli A., Ceni E., Simi L., and Baglioni S. Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br. J. Cancer 95 (2006) 879
Chalimoniuk M., King-Pospisil K., Pedersen W.A., Malecki A., Wylegala E., Mattson M.P., Hennig B., and Toborek M. Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C-mediated mechanism. J. Neurochem. 90 (2004) 629
Charo I.F., and Ransohoff R.M. Mechanisms of disease - the many roles of chemokines and chemokine receptors in inflammation. New Engl. J. Med. 354 (2006) 610
Chattopadhyay N., Singh D.P., Heese O., Godbole M.M., Sinohara T., Black P.M., and Brown E.M. Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J. Neurosci. Res. 61 (2000) 67
Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48
Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58 (2005) 963
Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059
Chen S.D., Wu H.Y., Yang D.I., Lee S.Y., Shaw F.Z., Lin T.K., Liou C.W., and Chuang Y.C. Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2. Biochem. Biophys. Res. Commun. 351 (2006) 198
Chopp M., Li Y., Jiang N., Zhang R.L., and Prostak J. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J. Cereb. Blood Flow Metab. 16 (1996) 578
Cimini A., Bernardo A., Cifone M.G., Di Marzio L., and Di Loreto S. TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 41 (2003) 3
Cimini A., Cristiano L., Colafarina S., Benedetti E., Di Loreto S., Festuccia C., Amicarelli F., Canuto R.A., and Ceru M.P. PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int. J. Cancer 117 (2005) 923
Collet P., Domenjoud L., Devignes M.D., Murad H., Schohn H., and Dauca M. The human semaphorin 6B gene is down regulated by PPARs. Genomics 83 (2004) 1141
Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radical Biol. Med. 41 (2006) 579
Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70
Colville-Nash P.R., Qureshi S.S., Willis D., and Willoughby D.A. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J. Immunol. 161 (1998) 978
Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 20 (2000) 558
Craft S., Asthana S., Schellenberg G., Baker L., Cherrier M., Boyt A.A., Martins R.N., Raskind M., Peskind E., and Plymate S. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. N. Y. Acad. Sci. 903 (2000) 222
Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., Plymate S., Latendresse S., Petrova A., Raskind M., Peskind E., Lofgreen C., and Grimwood K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70 (1999) 146
Cristiano L., Bernardo A., and Ceru M.P. Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J Neurocytol. 30 (2001) 671
Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., and Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 70 (1998) 1366
Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169 (2002) 6806
Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., and Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168 (2002) 2795
d'Abramo C., Massone S., Zingg J.M., Pizzuti A., Marambaud P., Dalla P.B., Azzi A., Marinari U.M., Pronzato M.A., and Ricciarelli R. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem. J. 391 (2005) 693-698
Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev., Immunol. 2 (2002) 748
Dehmer T., Heneka M.T., Sastre M., Dichgans J., and Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88 (2004) 494
Dehmer T., Lindenau J., Haid S., Dichgans J., and Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74 (2000) 2213
Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1. J. Biol. Chem. 274 (1999) 32048
Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., and Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23 (2003) 6264
Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., and Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193 (2001) 827
Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649
Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508
Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279
Ehrmann Jr. J., Vavrusova N., Collan Y., and Kolar Z. Peroxisome proliferator-activated receptors (PPARs) in health and disease. Biomed. Pap. Med. Fac. Palacky Univ. Olomouc Czech. Repub. 146 (2002) 11
Emmans V.C., Rodway H.A., Hunt A.N., and Lillycrop K.A. Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression. Biochem. Soc. Trans. 32 (2004) 840
Engelhardt B. Molecular mechanisms of T cell migration across the BBB in vivo. J. Neuroimmunol. 178 (2006) 32
Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., and Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142 (2001) 4195
Escriva H., Delaunay F., and Laudet V. Ligand binding and nuclear receptor evolution. BioEssays 22 (2000) 717
Farioli-Vecchioli S., Moreno S., and Ceru M.P. Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system. J. Neurocytol. 30 (2001) 21
Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., and Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?. Biochem. Pharmacol. 70 (2005) 177
Fuentealba R.A., Farias G., Scheu J., Bronfman M., Marzolo M.P., and Inestrosa N.C. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res. Brain Res. Rev. 47 (2004) 275
D. Geldmacher, G. Landreth, Pioglitazone in Alzheimer's Disease: Rationale and Clinical Trial Design, (2004) p. 397.
Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., and Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR gamma. Mol. Cell 25 (2007) 57
Gimble J.M., Robinson C.E., Wu X.Y., Kelly K.A., Rodriguez B.R., Kliewer S.A., Lehmann J.M., and Morris D.C. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 50 (1996) 1087
Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5 (2004) 419
Grommes C., Landreth G.E., Sastre M., Beck M., Feinstein D.L., Jacobs A.H., Schlegel U., and Heneka M.T. Inhibition of in vivo glioma growth and invasion by PPAR{gamma} agonist treatment. Mol. Pharmacol. 70 (2006) 1524-1533
Grommes C., Landreth G.E., Schlegel U., and Heneka M.T. The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J. Pharmacol. Exp. Ther. 313 (2005) 806
Han S.W., Greene M.E., Pitts J., Wada R.K., and Sidell N. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin. Cancer Res. 7 (2001) 98
Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., and Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2 (1996) 1017
Heneka M.T., Feinstein D.L., Galea E., Gleichmann M., Wullner U., and Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156
Heneka M.T., Gavrilyuk V., Landreth G.E., O'Banion M.K., Weinberg G., and Feinstein D.L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem. 85 (2003) 387
Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20 (2000) 6862
Heneka M.T., Landreth G.E., and Feinstein D.L. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann. Neurol. 49 (2001) 276
Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., van Leuven F., and Landreth G.E. Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and A beta 1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442
Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., and Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 906
Hull M., Lieb K., and Fiebich B.L. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr. Med. Chem. 9 (2002) 83
Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7531
Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., and Bing G.Y. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 100 (2007) 1375
Iadecola C., and Ross M.E. Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann. N. Y. Acad. Sci. 835 (1997) 203
t'Veld B.A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515
Inestrosa N.C., Godoy J.A., Quintanilla R.A., Koenig C.S., and Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304 (2005) 91
Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., and Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352 (2003) 203
Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., Mihara K., Moriguchi A., and Matsuoka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J. Pharmacol. Exp. Ther. 320 (2007) 1087
Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82
Jones D.C., and Daynes R.A. The nuclear hormone receptor PPAR alpha's ability to control T-bet transcription is due to its ability to regulate redox homeostasis within T cells. FASEB J. 16 (2002) A700
Kato M., Nagaya T., Fujieda M., Saito K., Yoshida J., and Seo H. Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines. Jpn. J. Cancer Res. 93 (2002) 660
Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T., and Sano H. 15-deoxy-Delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106 (2000) 189
Keller J.M., Collet P., Bianchi A., Huin C., Bouillaud-Kremarik P., Becuwe P., Schohn H., Domenjoud L., and Dauca M. Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease. Int. J. Dev. Biol. 44 (2000) 429
Kersten S., and Wahli W. Peroxisome proliferator activated receptor agonists. EXS 89 (2000) 141
Kiaei M., Kipiani K., Chen J.Y., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331
Kielian T., and Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 71 (2003) 315
Kim E.J., Kwon K.J., Park J.Y., Lee S.H., Moon C.H., and Baik E.J. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 941 (2002) 1
Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R.A.S., Graf K., Fleck E., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401 (2000) 259
Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., and Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 215
Klotz L., Schmidt M., Giese T., Sastre M., Knolle P., Klockgether T., and Heneka M.T. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175 (2005) 4948
Kreisler A., Gele P., Wiart J.F., Lhermitte M., Destee A., and Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res. 1135 (2007) 77
Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997) 779
Kudo M., Sugawara A., Uruno A., Takeuchi K., and Ito S. Transcription suppression of peroxisome proliferator-activated receptor gamma 2 gene expression by tumor necrosis factor alpha via an inhibition of CCAAT/enhancer-binding protein delta during the early stage of adipocyte differentiation. Endocrinology 145 (2004) 4948
Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Kervinen K., Kesaniemi Y.A., Riekkinen P.J., and Laakso M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315 (1997) 1045
Landreth G.E., and Heneka M.T. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol. Aging 22 (2001) 937
Lee B.C., Lee H.J., and Chung J.H. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci. Lett. 410 (2006) 141-145
Lee J., and Reding M. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem. Res. 32 (2007) 635-638
Lee S.C., Zhao M.L., Hirano A., and Dickson D.W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J. Neuropathol. Exp. Neurol. 58 (1999) 1163
Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406
Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403
Liu D.C., Zang C.B., Liu H.Y., Possinger K., Fan S.G., and Elstner E. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol. Sin. 25 (2004) 1312
E.Lovett-Racke A., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 (2004) 5790
Luchsinger J.A., Tang M.X., Stern Y., Shea S., and Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154 (2001) 635
Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., and Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280 (2005) 21453
Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., and Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 97 (2006) 435
Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., and Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim.-Forsch. 47 (1997) 29
Maggiora M., Bologna M., Ceru M.P., Possati L., Angelucci A., Cimini A., Miglietta A., Bozzo F., Margiotta C., Muzio G., and Canuto R.A. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int. J. Cancer 112 (2004) 909
Martin R., Mcfarland H.F., and Mcfarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10 (1992) 153
Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90 (2002) 703
Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., and Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 164 (2000) 6503
McGeer P.L., and McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26 (2002) 459
Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N.A., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., and Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58 (2006) 726
Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131
Morosetti R., Servidei T., Mirabella M., Rutella S., Mangiola A., Maira G., Mastrangelo R., and Koeffler H.P. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int. J. Oncol. 25 (2004) 493
Mukherjee R., Jow L., Croston G.E., and Paterniti Jr. J.R. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 272 (1997) 8071
Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40
Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707
Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 61 (2001) 6213
Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., and Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53 (1998) 14
Park K.S., Lee R.D., Kang S.K., Han S.Y., Park K.L., Yang K.H., Song Y.S., Park H.J., Lee Y.M., Yun Y.P., Oh K.W., Kim D.J., Yun Y.W., Hwang S.J., Lee S.E., and Hong J.T. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. Exp. Cell Res. 297 (2004) 424
Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 17 (2004) 500
Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199 (2006) 265
Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256
Pereira M.P., Hurtado O., Cardenas A., Alonso-Escolano D., Bosca L., Vivancos J., Nombela F., Leza J.C., Lorenzo P., Lizasoain I., and Moro M.A. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64 (2005) 797
Pereira M.P., Hurtado O., Cardenas A., Bosca L., Castillo J., Davalos A., Vivancos J., Serena J., Lorenzo P., Lizasoain I., and Moro M.A. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26 (2006) 218
Perez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvo S., Jordan J., Cena V., and Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J. Biol. Chem. 279 (2004) 8976
Pershadsingh H.A. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?. Expert Opin. Investig. Drugs 13 (2004) 215
Peters J.M., Lee S.S., Li W., Ward J.M., Gavrilova O., Everett C., Reitman M.L., Hudson L.D., and Gonzalez F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20 (2000) 5119
Polak P.E., Kalinin S., Dello Russo C., Gavrilyuk V., Sharp A., Peters J.M., Richardson J., Willson T.M., Weinberg G., and Feinstein D.L. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 168 (2005) 65
Posch M.G., Zang C., Mueller W., Lass U., and von Deimling A. Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med. Sci. Monit. 10 (2004) BR250-BR254
Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., and Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4565
Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006) 190
Raikwar H.P., Muthian G., Rajasingh J., Johnson C.N., and Bright J.J. PPAR gamma antagonists reverse the inhibition of neural antigen-specific Th-1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Delta(12,14)-Prostaglandin J(2). J. Neuroimmunol. 178 (2006) 76
Relton J.K., and Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29 (1992) 243
Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79
Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., and Poser S. Tumor-necrosis-factor-alpha messenger-Rna expression in patients with relapsing-remitting multiple-sclerosis is associated with disease-activity. Ann. Neurol. 37 (1995) 82
Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., and Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6 (2006) 246
Rodway H.A., Hunt A.N., Kohler J.A., Postle A.D., and Lillycrop K.A. Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells'. Biochem. J. 382 (2004) 83
Rosen E.D., and Spiegelman B.M. PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731
Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103
Saluja I., Granneman J.G., and Skoff R.P. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33 (2001) 191
Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796
Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 443
Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D.L., and Heneka M.T. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J. Leukoc. Biol. 75 (2004) 478
Schultze K., Bock B., Eckert A., Oevermann L., Ramacher D., Wiestler O., and Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11 (2006) 1503
Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., and Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64 (1995) 936
Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., and Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25 (2005) 7805
Servidei T., Morosetti R., Ferlini C., Cusano G., Scambia G., Mastrangelo R., and Koeffler H.P. The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol. Res. 14 (2004) 345
Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., and Greenberg J.H. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353
Smith S.A., Monteith G.R., Robinson J.A., Venkata N.G., May F.J., and Roberts-Thomson S.J. Effect of the peroxisome proliferator-activated receptor beta activator GW0742 in rat cultured cerebellar granule neurons. J. Neurosci. Res. 77 (2004) 240
Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., and Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52 (2005) 126
Strakova N., Ehrmann J., Dzubak P., Bouchal J., and Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J. Pharmacol. Exp. Ther. 309 (2004) 1239
Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104 (1999) 383
Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685
Sundararajan S., and Landreth G.E. Antiinflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect. 17 (2004) 229
Valentiner U., Carlsson M., Erttmann R., Hildebrandt H., and Schumacher U. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213 (2005) 157
Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653
Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., Weidner J., Mumford R., Webber R., Nathan C., Roberts A.B., Lippa C.F., and Sporn M.B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184 (1996) 1425
Wada K., Nakajima A., Katayama K., Kudo C., Shibuya A., Kubota N., Terauchi Y., Tachibana M., Miyoshi H., Kamisaki Y., Mayumi T., Kadowaki T., and Blumberg R.S. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem. 281 (2006) 12673
Waite K.J., Floyd Z.E., Arbour-Reily P., and Stephens J.M. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J. Biol. Chem. 276 (2001) 7062
Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., and Stemerman M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277 (2002) 34176
Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950
Watson G.S., and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS. Drugs 17 (2003) 27
Weydt P., and Moller T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. NeuroReport 16 (2005) 527
Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341
Woods J.W., Tanen M., Figueroa D.J., Biswas C., Zycband E., Moller D.E., Austin C.P., and Berger J.P. Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res. 975 (2003) 10
Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504
Yang G.Y., Gong C., Qin Z., Ye W., Mao Y., and Bertz A.L. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. NeuroReport 9 (1998) 2131
Yao C.J., Lai G.M., Chan C.F., Cheng A.L., Yang Y.Y., and Chuang S.E. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int. J. Cancer 118 (2006) 773
Zander T., Kraus J.A., Grommes C., Schlegel U., Feinstein D., Klockgether T., Landreth G., Koenigsknecht J., and Heneka M.T. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 81 (2002) 1052
Zhang R.L., Chopp M., Li Y., Zaloga C., Jiang N., Jones M.L., Miyasaka M., and Ward P.A. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 44 (1994) 1747
Zhao X.R., Ou Z.S., Grotta J.C., Waxham N., and Aronowki J. Peroxisome-proliferator-activated receptor-gamma (PPAR gamma) activation protects neurons from NMDA excitotoxicity. Brain Res. 1073 (2006) 460
Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22 (2005) 278
Zheng Z., and Yenari M.A. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol. Res. 26 (2004) 884
